Search Within

Sarat Chandarlapaty

  1. "Fresia Pareja Zea"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (17)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (39)
  2. Breast Medicine Service (39)
  3. Department of Medicine (39)
  4. Department of Pathology and Laboratory Medicine (39)
  5. GSK Faculty (39)
  6. Human Oncology and Pathogenesis Program (39)

More Groups

People
  1. Fresia Pareja Zea (39)
  2. Jorge Reis-Filho (33)
  3. Britta Weigelt (30)
  4. Hannah Wen (24)
  5. Pier Selenica (23)
  6. Edi Brogi (22)

More People

Years
  1. 2025 (6)
  2. 2024 (5)
  3. 2023 (7)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (11)

More Years

Publications
  1. Laboratory Investigation (8)
  2. Cancer Research (6)
  3. Annals of Oncology (4)
  4. Modern Pathology (4)
  5. npj Breast Cancer (4)
  6. Journal of Clinical Oncology (3)

More Publications

Publishers
  1. Nature Publishing Group (14)
  2. American Association for Cancer Research (7)
  3. American Society of Clinical Oncology (4)
  4. Nature Research (4)
  5. Oxford University Press (4)
  6. Wiley Blackwell (3)

More Publishers

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer
    Journal Article

    Boyer, J. A.; Rosen, E. Y.; Sharma, M.; Dorso, M. A.; Mai, N.; Amor, C.; Reiter, J. M.; Kannan, R.; Gadal, S.; Xu, J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2025)

    Fulltext@MSK | Save
  • Genomic landscape of breast cancer in elderly patients
    Journal Article

    Selenica, P.; Dopeso, H.; Repetto, M.; Basili, T.; Gazzo, A. M.; Schwartz, C. J.; Derakhshan, F.; Marra, A.; Ferrando, L.; Beets-Tan, R. G. H.; more...
    npj Breast Cancer (2025)

    Fulltext@MSK | Save
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Abdou, Y.; Melisko, M. E.; Pareja, F.; Weigelt, B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Co-occurrence of PI3K pathway gene alterations in endometrial cancer molecular subtypes at the single cell level
    Meeting Abstract

    Da Cruz Paula, A.; Zhu, Y.; Brown, D.; Pareja, F.; de Oliveira, T. B.; Dopeso, H.; da Silva, E. M.; Chandarlapaty, S.; Abu-Rustum, N.; Reis, J.; more...
    Laboratory Investigation (2025)

    Fulltext@MSK | Save
  • Germline genetic alterations in homologous recombination deficiency/DNA damage response genes in breast cancer
    Meeting Abstract

    Keske, A.; Terraf, P.; Gazzo, A.; Repetto, M.; Schwartz, C.; Ross, D.; Zhang, H.; Chandarlapaty, S.; Wen, H.; Brogi, E.; more...
    Laboratory Investigation (2025)

    Fulltext@MSK | Save
  • Multimodal histopathologic models stratify hormone receptor-positive early breast cancer
    Journal Article

    Boehm, K. M.; El Nahhas, O. S. M.; Marra, A.; Waters, M.; Jee, J.; Braunstein, L.; Schultz, N.; Selenica, P.; Wen, H. Y.; Weigelt, B.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • RB1 somatic alterations in ER-positive breast cancer: assessment of neuroendocrine differentiation
    Meeting Abstract

    Schwartz, C.; Marra, A.; Selenica, P.; da Silva, E. M.; Chandarlapaty, S.; Brogi, E.; Pareja, F.; Wen, H.
    Laboratory Investigation (2024)

    Fulltext@MSK | Save
  • A genomics-driven artificial intelligence–based model classifies breast invasive lobular carcinoma and discovers CDH1 inactivating mechanisms
    Journal Article

    Pareja, F.; Dopeso, H.; Wang, Y. K.; Gazzo, A. M.; Brown, D. N.; Banerjee, M.; Selenica, P.; Bernhard, J. H.; Derakhshan, F.; da Silva, E. M.; more...
    Cancer Research (2024)

    Fulltext@MSK | Save
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Carey, L. A.; Melisko, M. E.; Syldor, A.; Friedman, C.; Savoie, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • RB1 genetic alterations in estrogen receptor–positive breast carcinomas: Correlation with neuroendocrine differentiation
    Journal Article

    Schwartz, C. J.; Marra, A.; Selenica, P.; Gazzo, A.; Tan, K.; Ross, D.; Razavi, P.; Chandarlapaty, S.; Weigelt, B.; Reis-Filho, J. S.; more...
    Modern Pathology (2024)

    Fulltext@MSK | Save